CJC-1295 + Ipamorelin + GHRP-2 is a three-component peptide combination encountered in research and commercial peptide listings. The individual compounds have separate pharmacology and human research records, but the three-component blend should not be treated as a standardized or clinically validated combination.
It is a multi-compound research formulation containing a growth-hormone-releasing-hormone analogue (CJC-1295) together with two growth-hormone secretagogues (ipamorelin and GHRP-2). FDA materials document commercial marketing of products containing CJC-1295, GHRP-2 and ipamorelin together, but the available record does not establish one universal ratio, standardized formulation, or controlled clinical evidence demonstrating that this exact three-component combination is effective or safe.
Visual created entirely with HTML/CSS. No Shopify image upload or external image asset is required.
The stack contains three chemically distinct peptides. They do not become a single new peptide when placed in the same vial. Each component retains its own molecular identity and its own mass. When the same final liquid volume is shared by all three components, each concentration must be calculated independently.
All three share the same final liquid volume.
CJC-1295 + Ipamorelin + GHRP-2 is better described as a multi-compound formulation or market/research combination than as a single standardized pharmaceutical formulation. FDA review documents websites marketing multi-ingredient powders containing CJC-1295, GHRP-2 and ipamorelin, but the existence of those products does not establish one medically validated composition. :contentReference[oaicite:1]{index=1}
| Term | Classification | What it means |
|---|---|---|
| CJC-1295 + Ipamorelin + GHRP-2 | Combination name | A descriptive name for three compounds appearing together in research/commercial contexts. |
| Single standardized drug | Not established | The three-component combination should not be represented as one universally standardized pharmaceutical product. |
| Clinical protocol | Not established | Individual studies do not establish a validated protocol for the three-component blend. |
The three components operate through related but distinct parts of the growth-hormone regulatory system. Human research exists for each compound separately, but those findings should not be interpreted as proof that the three-compound formulation has the same effects.
CJC-1295 is a long-acting analogue of growth-hormone-releasing hormone (GHRH). Human studies have examined its pharmacokinetics and effects on GH and IGF-1 secretion.
Importantly, the term CJC-1295 can appear in product listings with different descriptions concerning DAC status. The specific chemical form should therefore be identified from the research material or analytical documentation rather than assumed.
Ipamorelin is a growth-hormone-releasing peptide studied for its ability to stimulate GH secretion. Human pharmacokinetic and pharmacodynamic research has characterized its GH response.
Research on ipamorelin should be distinguished from claims about long-term benefits of combining it with CJC-1295 or GHRP-2.
GHRP-2 is a synthetic growth-hormone-releasing peptide and ghrelin receptor agonist. Human studies have investigated GH release, appetite effects and its interaction with GHRH-mediated GH secretion.
Individual GHRP-2 findings do not establish the efficacy or safety of a CJC-1295 + Ipamorelin + GHRP-2 blend.
Randomized placebo-controlled studies in healthy adults found that CJC-1295 produced dose-dependent increases in GH and IGF-1, with sustained effects following administration. :contentReference[oaicite:2]{index=2}
A separate human study found increased trough and mean GH secretion with preserved pulsatility following CJC-1295 administration. :contentReference[oaicite:3]{index=3}
Human pharmacokinetic/pharmacodynamic research found that ipamorelin produces a GH response with a relatively short terminal half-life and a measurable concentration-response relationship. :contentReference[oaicite:4]{index=4}
Ipamorelin has also been investigated clinically in contexts such as postoperative ileus, which is different from evidence for a peptide optimization or performance stack. :contentReference[oaicite:5]{index=5}
Human studies demonstrate that GHRP-2 can stimulate GH secretion. Research has also shown that GHRP-2 can influence food intake, illustrating that its biological effects extend beyond GH release. :contentReference[oaicite:6]{index=6}
Research has also evaluated GHRH/GHRP-2 combinations, but that does not establish the specific three-component combination covered on this page. :contentReference[oaicite:7]{index=7}
FDA materials document the existence of marketed multi-ingredient preparations containing CJC-1295, GHRP-2 and ipamorelin, including products described as CJC-1295-GHRP-2-ipamorelin. However, this is evidence of market/compounding activity—not evidence that the exact three-component formulation has been established as an effective or safe clinical protocol. :contentReference[oaicite:8]{index=8}
Yes. Each component has independent scientific or clinical research.
Not established as a standardized clinical formulation.
Individual effects cannot be added together to claim efficacy of the complete blend.
Individual safety observations cannot establish the safety profile of the three-compound mixture.
CJC-1295 terminology requires particular care. Product and research descriptions can distinguish CJC-1295 associated with the drug-affinity complex (DAC) from products described as CJC-1295 without DAC. These should not automatically be treated as interchangeable materials.
| Term | General description | Why it matters |
|---|---|---|
| CJC-1295 with DAC | Long-acting CJC-1295 formulation associated with albumin-binding properties. | Pharmacokinetic behavior differs from short-acting descriptions. |
| CJC-1295 without DAC | Product/research terminology used for shorter-acting material. | Should not be assumed to have the same pharmacokinetics as CJC-1295 DAC. |
| Unspecified CJC-1295 | Label does not clearly identify the form. | The exact identity should be verified before interpreting literature or calculating concentrations. |
There is no evidence-based universal vial ratio that should be presented as the standard CJC-1295 + Ipamorelin + GHRP-2 formulation. Online research products and compounded preparations may use different amounts, forms and total vial masses.
| Formulation category | CJC-1295 | Ipamorelin | GHRP-2 | Status |
|---|---|---|---|---|
| Three-component blend | Variable | Variable | Variable | Not standardized |
| Equal-mass example | 2 mg* | 2 mg* | 2 mg* | Math example only |
| Vendor-specific preparation | Must be determined from the actual product label / COA. | Verify | ||
*The 2 mg / 2 mg / 2 mg example is intentionally hypothetical and is included solely to demonstrate multi-component concentration arithmetic. It is not presented as a common formulation, dose, or recommended vial.
Visual created with HTML/CSS. No image file is required.
For a multi-component vial, the correct mathematical approach is to calculate the concentration of each component separately. Adding the component masses together and calling the result the concentration of every ingredient is incorrect.
The following table uses the deliberately hypothetical 2 mg CJC-1295 + 2 mg Ipamorelin + 2 mg GHRP-2 example. It demonstrates the mathematics only.
| Component | 1 mL | 2 mL | 3 mL | 5 mL |
|---|---|---|---|---|
| CJC-1295 — 2 mg | 2 mg/mL | 1 mg/mL | 0.667 mg/mL | 0.400 mg/mL |
| Ipamorelin — 2 mg | 2 mg/mL | 1 mg/mL | 0.667 mg/mL | 0.400 mg/mL |
| GHRP-2 — 2 mg | 2 mg/mL | 1 mg/mL | 0.667 mg/mL | 0.400 mg/mL |
This is where multi-component concentration logic becomes particularly important. Consider a hypothetical research vial containing:
If the final liquid volume were 4 mL, each component would be calculated independently:
| Component | Mass | Final volume | Concentration |
|---|---|---|---|
| CJC-1295 | 5 mg | 4 mL | 1.25 mg/mL |
| Ipamorelin | 2 mg | 4 mL | 0.50 mg/mL |
| GHRP-2 | 1 mg | 4 mL | 0.25 mg/mL |
The combined mass is 8 mg, but it would be incorrect to label all three components as “2 mg/mL.” The total 8 mg describes the total peptide mass, not the individual concentration of each peptide.
Increasing the final liquid volume dilutes every component proportionally. Decreasing the final liquid volume increases concentration mathematically. The mass of each peptide does not change simply because the liquid volume changes.
| Final volume | 5 mg CJC-1295 | 2 mg Ipamorelin | 1 mg GHRP-2 |
|---|---|---|---|
| 1 mL | 5.00 mg/mL | 2.00 mg/mL | 1.00 mg/mL |
| 2 mL | 2.50 mg/mL | 1.00 mg/mL | 0.50 mg/mL |
| 3 mL | 1.667 mg/mL | 0.667 mg/mL | 0.333 mg/mL |
| 5 mL | 1.00 mg/mL | 0.40 mg/mL | 0.20 mg/mL |
Use the BacScience Universal BAC Water Calculator for concentration mathematics. For a multi-component vial, calculate each ingredient independently using its own starting mass and the same final liquid volume.
Open the Universal BAC Water CalculatorThe Universal BAC Water Calculator is primarily structured around single-compound concentration mathematics. For a blend, repeat the calculation for every component:
Do not enter the combined peptide mass and use the resulting number as the concentration of every ingredient.
The primary limitation is the absence of a clearly established clinical evidence base for a standardized CJC-1295 + Ipamorelin + GHRP-2 formulation.
Commercial or research listings may differ in peptide identity, CJC-1295 variant, amount per vial and component ratios.
A positive result for one compound does not establish the same result when that compound is combined with two additional secretagogues.
Short-term pharmacodynamic observations cannot by themselves establish long-term safety or clinical benefit of a multi-peptide formulation.
Regulatory status should be evaluated separately from scientific interest. FDA materials identify CJC-1295, GHRP-2 and ipamorelin in discussions of compounded peptide substances and describe specific concerns involving peptide impurities, aggregation and characterization. For CJC-1295, FDA also notes limited clinical data and reports of serious adverse events including increased heart rate and systemic vasodilatory reaction. :contentReference[oaicite:10]{index=10}
FDA's review similarly identifies concerns around GHRP-2 and ipamorelin, including potential immunogenicity associated with aggregation and peptide-related impurities. :contentReference[oaicite:11]{index=11}
These regulatory observations reinforce why a research listing, laboratory formulation or commercially marketed blend should not be automatically presented as an approved therapeutic protocol.
| Question | Current interpretation |
|---|---|
| Are all three compounds individually studied? | Yes |
| Is one universal three-component formulation established? | No |
| Are CJC-1295 + GHRP-2 + Ipamorelin products documented in the market? | Yes |
| Does market availability prove clinical efficacy? | No |
| Can component studies be used as proof of blend efficacy? | No |
| Does changing liquid volume change peptide mass? | No |
| Does changing liquid volume change concentration? | Yes |
It is a three-component peptide combination consisting of CJC-1295, ipamorelin and GHRP-2. It is encountered in research and commercial peptide contexts, but it should not be represented as one standardized clinically validated formulation.
No universal standardized ratio was established in the evidence reviewed for this page. FDA materials document products containing the three compounds but do not establish a single validated ratio. :contentReference[oaicite:12]{index=12}
Individual components have been studied in humans, but those studies should not be represented as controlled clinical evidence for the exact three-component blend.
Yes. Randomized placebo-controlled human studies have investigated CJC-1295 pharmacokinetics and its effects on GH and IGF-1 secretion. :contentReference[oaicite:13]{index=13}
Yes. Human pharmacokinetic/pharmacodynamic research has examined ipamorelin and its GH response. Clinical research has also evaluated ipamorelin in postoperative ileus. :contentReference[oaicite:14]{index=14}
Human studies show that GHRP-2 can stimulate GH secretion. Studies have also investigated interactions between GHRH and GHRP-2. :contentReference[oaicite:15]{index=15}
Yes. If peptide mass stays constant, increasing the final liquid volume decreases concentration according to mass divided by volume.
No. Each component has its own concentration. The individual mass of each component is divided by the shared final liquid volume.
No. Total peptide mass and individual peptide concentration are different measurements. Each component must be calculated from its own labeled mass.
DAC refers to the drug-affinity-complex terminology associated with long-acting CJC-1295. CJC-1295 products described as without DAC should not automatically be assumed to have identical pharmacokinetics. The exact material should be verified from the product documentation.
Scientific and regulatory information can change. Re-check primary literature, regulatory documents, product identity and analytical documentation before updating formulation-specific claims.